Consider it necessary to examine these two molecular pathways for anaplastic thyroid carcinoma because BRAF and MEK inhibitors have been shown beneficial in treating anaplastic thyroid carcinoma in numerous prior clinical trials [39]. This evidence concerns the gene MAP2K7 and thyroid gland undifferentiated (anaplastic) carcinoma.